Stock Analysis
- United Kingdom
- /
- Biotech
- /
- AIM:OPTI
OptiBiotix Health Full Year 2022 Earnings: EPS: UK£0.029 (vs UK£0.071 in FY 2021)
OptiBiotix Health (LON:OPTI) Full Year 2022 Results
Key Financial Results
- Net income: UK£2.59m (down 59% from FY 2021).
- EPS: UK£0.029 (down from UK£0.071 in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
OptiBiotix Health shares are down 17% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 4 warning signs for OptiBiotix Health (of which 3 are a bit unpleasant!) you should know about.
Valuation is complex, but we're helping make it simple.
Find out whether OptiBiotix Health is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:OPTI
OptiBiotix Health
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulators primarily in the United Kingdom.
Flawless balance sheet with weak fundamentals.